[Correlation of genetic and cytogenetic alterations in pathological aggressiveness urothelial carcinoma of the bladder: Performance of BCA-1, a mini-array comparative genomic hybridisation-based test]

Urothelial carcinomas are the fourth leading cause of cancer in humans. Their incidence is increasing by more than 50% in 25 years. The superficial forms (70% cases) require a close active surveillance to identify frequent recurrences and progression to invasive stage. Our main goal was to identify prognostic molecular markers for bladder cancer that could be used alone or in combination in routine clinical practice. In this aim, we evaluated the capability of the BCA-oligo test based on a CGH array to correctly classify tumoral grade/stage.

Urinary DNA was extracted from 81 patients with superficial bladder cancer and has been hybridized on the BCA-oligo array. The results from the molecular analysis were correlated with the tumoral grade and stage.

Several chromosomal alterations were significantly more frequent in tumors of higher grade and more advanced stage. A significant association was observed between a high grade and the presence of one of these alterations: loss on 6p, gain on 8q or 13q, loss or gain on 9q or 11q, with an odds ratio of 6.91 (95% CI=2.20-21.64; P=0.0009). Moreover, a significant association was found between a more advanced stage (pT1) and the presence of one of these alterations: loss on 6p, gain on 8q, loss or gain on 5p, with an odds ratio of 15.2 (95% CI=3.71-62.58; P=0.0002).

Our results showed that molecular analyses of superficial bladder cancers based on urinary DNA and the BCA-oligo test could be used as prognostic factor for the tumor evolution, allowing then a more adapted clinical management.

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie. 2017 May 30 [Epub ahead of print]

P Léon, G Cancel Tassin, K Sighar, E Compérat, C Gaffory, V Ondet, S Hugonin, M Audouin, S Doizi, O Traxer, C Ciofu, M Rouprêt, R Lacave, O Cussenot

GRC n(o) 5, ONCOTYPE-URO, institut universitaire de cancérologie, UPMC université Paris 06, 75020 Paris, France; Département de chirurgie urologique, CHU de Reims, rue Cognacq-Jay, 51000 Reims, France. Electronic address: ., GRC n(o) 5, ONCOTYPE-URO, institut universitaire de cancérologie, UPMC université Paris 06, 75020 Paris, France; CeRePP, 75020 Paris, France., Arraygenomics, 78960 Voisins-le-Bretonneux, France., GRC n(o) 5, ONCOTYPE-URO, institut universitaire de cancérologie, UPMC université Paris 06, 75020 Paris, France; CeRePP, 75020 Paris, France; Département d'anatomopathologie, hôpital de la Pitié-Salpétrière, UPMC université Paris 06, AP-HP, 75013 Paris, France., GRC n(o) 5, ONCOTYPE-URO, institut universitaire de cancérologie, UPMC université Paris 06, 75020 Paris, France; CeRePP, 75020 Paris, France; Département de chirurgie urologique, hôpital Tenon, UPMC université Paris 06, AP-HP, 75020 Paris, France., Département de biologie tumorale, hôpital Tenon, UPMC université Paris 06, AP-HP, 75020 Paris, France., GRC n(o) 5, ONCOTYPE-URO, institut universitaire de cancérologie, UPMC université Paris 06, 75020 Paris, France; Département de chirurgie urologique, hôpital Tenon, UPMC université Paris 06, AP-HP, 75020 Paris, France., Département de chirurgie urologique, hôpital Tenon, UPMC université Paris 06, AP-HP, 75020 Paris, France., GRC n(o) 5, ONCOTYPE-URO, institut universitaire de cancérologie, UPMC université Paris 06, 75020 Paris, France; CeRePP, 75020 Paris, France; Département de chirurgie urologique, hôpital de la Pitié-Salpétrière, UPMC université Paris 06, AP-HP, 75013 Paris, France.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe